Document is current
Any future updates will be listed below
-
Authors
Ghatak, Swagata
Dolatabadi, Nima
Gao, Richard
Wu, Yin
Scott, Henry
Trudler, Dorit
Sultan, Abdullah
Ambasudhan, Rajesh
Nakamura, Tomohiro https://orcid.org/0000-0002-4246-7771
Masliah, Eliezer
Talantova, Maria
Voytek, Bradley
Lipton, Stuart A.
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (R01 GM134363)
- License Information
-
More Information
Article History
Received: 14 November 2019
Revised: 27 April 2020
Accepted: 1 May 2020
First Online: 29 May 2020
Change Date: 8 May 2025
Change Type: Update
Change Details: In response to the finding of partially duplicated images in a supplemental figure (Fig. S8a,b) to Ghatak et al., we have now corrected panels a and b, which appear now correct. The legend and the rest of this supplemental figure remain unchanged.
Compliance with ethical standards
:
: The authors declare that SAL is an inventor on worldwide patents for the use of memantine and NitroSynapsin for neurodegenerative and neurodevelopmental disorders. Per Harvard University guidelines, SAL participates in a royalty-sharing agreement with his former institution Boston Children’s Hospital/Harvard Medical School, which licensed the drug memantine (Namenda®) to Forest Laboratories, Inc./Actavis/Allergan, Inc. NitroSynapsin is licensed to EuMentis Therapeutics, Inc. The other authors declare that they have no conflict of interest.
